Ixotatug Vedotin

**Semantic type:** Pharmacologic Substance

**Definition:** An antibody-drug conjugate (ADC) composed of ixotatug, a humanized monoclonal antibody directed against the tumor-associated antigen (TAA) claudin 6 (CLDN6; CLDN-6), linked to the auristatin derivative monomethyl auristatin E (MMAE) via a cleavable linker, with potential antineoplastic activity. Upon administration of ixotatug vedotin, the anti-CLDN6 antibody moiety targets and binds to CLDN6-expressing tumor cells. Upon binding, internalization, and linker cleavage, MMAE is released. MMAE binds to tubulin and inhibits its polymerization, resulting in G2/M phase arrest and tumor cell apoptosis. This induces cell death in CLDN6-expressing cancer cells. CLDN6, a transmembrane tight-junction protein and embryonic antigen, is overexpressed on a variety of tumor cells but is not expressed on normal, healthy adult cells.

**Synonyms:** - ADC TORL-1-23 - Anti-CLDN6 ADC TORL-1-23 - Anti-CLDN6 Antibody-drug Conjugate TORL-1-23 - Anti-CLDN6/MMAE ADC TORL-1-23 - IXOTATUG VEDOTIN - TORL 1-23 - TORL-1-23 - TORL1-23